EA201591279A1 - Новые фрагменты антител, их композиции и способы применения - Google Patents

Новые фрагменты антител, их композиции и способы применения

Info

Publication number
EA201591279A1
EA201591279A1 EA201591279A EA201591279A EA201591279A1 EA 201591279 A1 EA201591279 A1 EA 201591279A1 EA 201591279 A EA201591279 A EA 201591279A EA 201591279 A EA201591279 A EA 201591279A EA 201591279 A1 EA201591279 A1 EA 201591279A1
Authority
EA
Eurasian Patent Office
Prior art keywords
constant regions
compositions
applications
antibody fragments
new antibody
Prior art date
Application number
EA201591279A
Other languages
English (en)
Other versions
EA031536B1 (ru
Inventor
Элиза Винья
Паоло Микьели
Паоло Мария Комольо
Original Assignee
Метересис Транслейшнл Рисеч С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метересис Транслейшнл Рисеч С.А. filed Critical Метересис Транслейшнл Рисеч С.А.
Publication of EA201591279A1 publication Critical patent/EA201591279A1/ru
Publication of EA031536B1 publication Critical patent/EA031536B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Предложен фрагмент антитела, содержащий первый полипептид, содержащий вариабельную область легкой цепи и две константные области, и второй полипептид, содержащий вариабельную область тяжелой цепи и две константные области, в котором две константные области цепи представляют собой константные области легкой цепи и две константные области представляют собой константные области тяжелой цепи СН1.
EA201591279A 2013-01-09 2014-01-07 Новые фрагменты антител, их композиции и способы применения EA031536B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000012A ITTO20130012A1 (it) 2013-01-09 2013-01-09 Nuovi frammenti anticorpali, relative composizioni ed usi
PCT/IB2014/058098 WO2014108829A1 (en) 2013-01-09 2014-01-07 New antibody fragments, compositions and uses thereof

Publications (2)

Publication Number Publication Date
EA201591279A1 true EA201591279A1 (ru) 2015-11-30
EA031536B1 EA031536B1 (ru) 2019-01-31

Family

ID=47790367

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591279A EA031536B1 (ru) 2013-01-09 2014-01-07 Новые фрагменты антител, их композиции и способы применения

Country Status (28)

Country Link
US (2) US9975952B2 (ru)
EP (1) EP2943510B1 (ru)
JP (1) JP6382842B2 (ru)
KR (1) KR102155392B1 (ru)
CN (1) CN104968684B (ru)
AU (1) AU2014206130A1 (ru)
BR (1) BR112015016447A8 (ru)
CA (1) CA2896929C (ru)
CL (1) CL2015001939A1 (ru)
DK (1) DK2943510T3 (ru)
EA (1) EA031536B1 (ru)
ES (1) ES2674491T3 (ru)
HR (1) HRP20180917T1 (ru)
HU (1) HUE037843T2 (ru)
IL (1) IL239704B (ru)
IT (1) ITTO20130012A1 (ru)
LT (1) LT2943510T (ru)
ME (1) ME03080B (ru)
MX (1) MX360258B (ru)
PH (1) PH12015501539A1 (ru)
PL (1) PL2943510T3 (ru)
PT (1) PT2943510T (ru)
RS (1) RS57286B1 (ru)
SG (1) SG11201505114VA (ru)
SI (1) SI2943510T1 (ru)
TR (1) TR201808826T4 (ru)
WO (1) WO2014108829A1 (ru)
ZA (1) ZA201504748B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800003875A1 (it) * 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
KR102433184B1 (ko) * 2018-12-07 2022-08-17 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
CN113480645B (zh) * 2021-07-16 2022-11-11 甘肃中科博瑞生物工程有限公司 一种抗幽门螺旋杆菌重组抗体、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
NZ547438A (en) 2003-12-19 2010-01-29 Genentech Inc Monovalent antibody fragments useful as therapeutics
RU2398777C2 (ru) * 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
CN101061140B (zh) * 2004-09-17 2015-07-01 多曼蒂斯有限公司 单价结合cd40l的组合物和应用方法
DK1981981T3 (da) * 2006-02-06 2011-09-26 Metheresis Translational Res Sa Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter
AU2007245181A1 (en) * 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-Met
JP2010535032A (ja) 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP6147670B2 (ja) * 2010-12-22 2017-06-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 改善された半減期を有する修飾された抗体
MY171038A (en) 2011-08-23 2019-09-23 Roche Glycart Ag Bispecific antigen binding molecules

Also Published As

Publication number Publication date
PL2943510T3 (pl) 2018-09-28
US20180237527A1 (en) 2018-08-23
DK2943510T3 (en) 2018-07-02
CL2015001939A1 (es) 2016-04-01
SG11201505114VA (en) 2015-07-30
SI2943510T1 (en) 2018-08-31
EP2943510A1 (en) 2015-11-18
EP2943510B1 (en) 2018-05-23
ZA201504748B (en) 2019-11-27
IL239704A0 (en) 2015-08-31
HRP20180917T1 (hr) 2018-08-10
CA2896929A1 (en) 2014-07-17
JP6382842B2 (ja) 2018-08-29
RS57286B1 (sr) 2018-08-31
ITTO20130012A1 (it) 2014-07-10
HUE037843T2 (hu) 2018-09-28
JP2016503069A (ja) 2016-02-01
US9975952B2 (en) 2018-05-22
CN104968684B (zh) 2019-06-28
ME03080B (me) 2019-01-20
US20160017044A1 (en) 2016-01-21
MX360258B (es) 2018-10-26
MX2015008779A (es) 2016-03-31
CA2896929C (en) 2020-09-29
TR201808826T4 (tr) 2018-07-23
CN104968684A (zh) 2015-10-07
BR112015016447A8 (pt) 2018-01-23
ES2674491T3 (es) 2018-07-02
US10351628B2 (en) 2019-07-16
KR102155392B1 (ko) 2020-09-11
AU2014206130A1 (en) 2015-07-30
PT2943510T (pt) 2018-07-02
LT2943510T (lt) 2018-07-10
IL239704B (en) 2019-03-31
EA031536B1 (ru) 2019-01-31
WO2014108829A1 (en) 2014-07-17
PH12015501539A1 (en) 2015-10-05
KR20150103283A (ko) 2015-09-09

Similar Documents

Publication Publication Date Title
CY1124993T1 (el) Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
EA202092435A2 (ru) Моноклональные антитела против bcma
CY1123236T1 (el) Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
CY1122653T1 (el) Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων
EA201791562A1 (ru) Антигены цитомегаловируса и их применения
ECSP18000844A (es) Anticuerpos de unión a tau
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201690314A1 (ru) Анти-garp-белок и его применения
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
BR112018010891A2 (pt) anticorpos e fragmentos de anticorpos para a conjugação específica do sítio
BR112018010360A2 (pt) fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
EA201690443A1 (ru) Биспецифические моновалентные диатела, которые способны связываться с cd123 и cd3, и их применения
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
ECSP18000887A (es) Anticuerpos de unión a tau
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM